Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
This approval is a significant achievement in expanding the availability of this critical therapeutic,
JCI accreditation is recognized globally
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Subscribe To Our Newsletter & Stay Updated